Effects of pioglitazone on visceral fat metabolic activity in impaired glucose tolerance or type 2 diabetes mellitus

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 11, 2013, Pages 4438-4445

  Kodama, Norihiro ^a   Tahara, Nobuhiro ^a   Tahara, Atsuko ^a   Honda, Akihiro ^a   Nitta, Yoshikazu ^a   Mizoguchi, Minori ^a   Kaida, Hayato ^b   Ishibashi, Masatoshi ^b   Abe, Toshi ^b   Ikeda, Hisao ^a   Narula, Jagat ^c   Fukumoto, Yoshihiro ^a   Yamagishi, Sho Ichi ^a   Imaizumi, Tsutomu ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Positron Emission Tomography Center   (Japan)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLIMEPIRIDE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PIOGLITAZONE;

AGED; ANTIDIABETIC ACTIVITY; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INTRAABDOMINAL FAT; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SUBCUTANEOUS FAT; TREATMENT DURATION;

ADMINISTRATION, ORAL; AGED; BODY FAT DISTRIBUTION; DIABETES MELLITUS, TYPE 2; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE INTOLERANCE; HUMANS; HYPOGLYCEMIC AGENTS; INTRA-ABDOMINAL FAT; MALE; MIDDLE AGED; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; SUBCUTANEOUS FAT; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84887456350     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-2920     Document Type: Article

References (40)

1. Swinburn BA, Sacks G, Hall KD, et al. The global obesity pandemic: shaped by global drivers and local environments. Lancet. 2011;378: 804-814.
2. World Health Organization. Obesity and overweight. Fact sheet No311. Updated March 2013. Available at: http://www.who.int/ mediacentre/factsheets/ fs311/en/.
3. Novak NL, Brownell KD. Role of policy and government in the obesity epidemic. Circulation. 2012;126: 2345-2352.
4. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011;11: 85-97.
5. Yusuf S, Hawken S, Ounpuu S, et al; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364: 937-952.
6. Larsson B, Björntorp P, Tibblin G. The health consequences of moderate obesity. Int J Obes. 1981;5: 97-116.
7. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow- up of participants in the Framingham Heart Study. Circulation. 1983;67: 968-977.
8. RexrodeKM,Hennekens CH, WillettWC,et al.Aprospective study of body mass index, weight change, and risk of stroke in women. JAMA. 1997;277: 1539-1545.
9. Yoshizumi T, Nakamura T, Yamane M, et al. Abdominal fat: standardized technique for measurement at CT. Radiology. 1999;211: 283-286.
10. Lee S, Janssen I, Ross R. Interindividual variation in abdominal subcutaneous and visceral adipose tissue: influence of measurement site. J Appl Physiol. 2004;97: 948-954.
11. Christen T, Sheikine Y, Rocha VZ, et al. Increased glucose uptake in visceral versus subcutaneous adipose tissue revealed by PET imaging. JACC Cardiovasc Imaging. 2010;3: 843-851.
12. Skurk T, Alberti-Huber C, Herder C, Hauner H. Relationship between adipocyte size and adipokine expression and secretion. J Clin Endocrinol Metab. 2007;92: 1023-1033.
13. Miyazaki Y, Mahankali A, Matsuda M, et al. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care. 2001;24: 710-719.
14. Satoh N, Ogawa Y, Usui T, et al. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care. 2003;26: 2493-2499.
15. Dormandy JA, Charbonnel B, Eckland DJ, et al; PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366: 1279-1289.
16. Pfützner A, Marx N, Lübben G, et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol. 2005; 45: 1925-1931.
17. Hallakou S, Doaré L, Foufelle F, et al. Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat. Diabetes. 1997;46: 1393-1399.
18. Spiegelman BM. PPAR-γ: adipogenic regulator and thiazolidinedione receptor. Diabetes. 1998;47: 507-514.
19. Lambe KG, Tugwood JD. A human peroxisome-proliferator-activated receptor γ is activated by inducers of adipogenesis, including thiazolidinedione drugs. Eur J Biochem. 1996;239: 1-7.
20. Miyazaki Y, Mahankali A, Matsuda M, et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab. 2002;87: 2784-2791.
21. Hirose H, Kawai T, Yamamoto Y, et al. Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes. Metabolism. 2002;51: 314-317.
22. Jonker JT,LambHJ, van der MeerRW,et al. Pioglitazone compared with metformin increases pericardial fat volume in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2010;95: 456-460.
23. Basu A, Jensen MD, McCann F, Mukhopadhyay D, Joyner MJ, Rizza RA. Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes. Diabetes Care. 2006;29: 510-514.
24. American Diabetes Association. Standards of medical care in diabetes - 2012. Diabetes Care. 2012;35(suppl 1):S11-S63.
25. Tahara N, Yamagishi S, Tahara A, et al. Adiponectin is inversely associated with ratio of serum levels ofAGEstosRAGEand vascular inflammation. Int J Cardiol. 2012;158: 461-462.
26. Hoelzel W, Weykamp C, Jeppsson JO, et al; IFCC Working Group onHbA1cStandardization. IFCC reference system for measurement of hemoglobin A1c in human blood and the national standardization schemes in the United States, Japan, and Sweden: a methodcomparison study. Clin Chem. 2004;50: 166-174.
27. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes. 1996;45: 1661-1669.
28. Galic S, Oakhill JS, Steinberg GR. Adipose tissue as an endocrine organ. Mol Cell Endocrinol. 2010;316: 129-139.
29. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun. 1996;221: 286-289.
30. Trayhurn P, Beattie JH. Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ. Proc Nutr Soc. 2001;60: 329-339.
31. Gustafson B, Hammarstedt A, Andersson CX, Smith U. Inflamed adipose tissue: a culprit underlying the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol. 2007;27:2276- 2283.
32. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003;112: 1796-1808.
33. Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003;112: 1821-1830.
34. Tawakol A, Migrino RQ, Bashian GG, et al. In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol. 2006;48: 1818-1824.
35. Tahara N, Kai H, Yamagishi S, et al. Vascular inflammation evaluated by [18F]-fluorodeoxyglucose positron emission tomography is associated with the metabolic syndrome. JAmColl Cardiol. 2007; 49: 1533-1539.
36. Bahceci M, Gokalp D, Bahceci S, Tuzcu A, Atmaca S, Arikan S. The correlation between adiposity and adiponectin, tumor necrosis factor α, interleukin-6 and high sensitivity C-reactive protein levels. Is adipocyte size associated with inflammation in adults? J Endocrinol Invest. 2007;30: 210-214.
37. de Souza CJ, Eckhardt M, Gagen K, et al. Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance. Diabetes. 2001;50: 1863-1871.
38. Takahashi M, Kamei Y, Ezaki O. Mest/Peg1 imprinted gene enlarges adipocytes and is a marker of adipocyte size. Am J Physiol Endocrinol Metab. 2005;288:E117-E124.
39. Wilcox R, Bousser MG, Betteridge DJ, et al PROactive Investigators. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke. 2007;38: 865-873.
40. Erdmann E, Dormandy JA, Charbonnel B, et al PROactive Investigators. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol. 2007;49: 1772-1780.